Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01989598 · OUTCOME

Detection of RAS and RAF Mutations Using cfDNA

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2022-03-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
MUTATIONS
Interval / dispersion
Not reported
Time frame
Baseline and every even cycle and at progression, an average of 9 cycles (9 months)

What was measured

Ultra-deep sequencing will be performed on cfDNA to assess the feasibility of detecting mutations of NRAS, KRAS and BRAF from peripheral blood samples.

Analysis population: 64 cfDNA specimens from 53 Myeloma patients including 13 patients from this trial that were included in this analysis

Groups in this outcome

Detection of KRAS Mutations Using cfDNA

Ultra-deep sequencing will be performed on cfDNA to assess the feasibility of detecting mutations of KRAS from peripheral blood samples.

Detection of NRAS Mutations Using cfDNA

Ultra-deep sequencing will be performed on cfDNA to assess the feasibility of detecting mutations of NRAS from peripheral blood samples.

Detection of BRAF Mutations Using cfDNA

Ultra-deep sequencing will be performed on cfDNA to assess the feasibility of detecting mutations of BRAF from peripheral blood samples.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Detection of KRAS Mutations Using cfDNA22
Detection of NRAS Mutations Using cfDNA13
Detection of BRAF Mutations Using cfDNA7

Reported measurements

Source class 1
Values in MUTATIONS · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Detection of KRAS Mutations Using cfDNA10Not reportedNot reportedNot reportedNot reported
Detection of NRAS Mutations Using cfDNA2Not reportedNot reportedNot reportedNot reported
Detection of BRAF Mutations Using cfDNA2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        10
      2. group Id
        OG001
        value
        2
      3. group Id
        OG002
        value
        2
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    2. group Id
      OG001
      value
      13
    3. group Id
      OG002
      value
      7
    units
    Participants
description
Ultra-deep sequencing will be performed on cfDNA to assess the feasibility of detecting mutations of NRAS, KRAS and BRAF from peripheral blood samples.
groups
  1. description
    Ultra-deep sequencing will be performed on cfDNA to assess the feasibility of detecting mutations of KRAS from peripheral blood samples.
    id
    OG000
    title
    Detection of KRAS Mutations Using cfDNA
  2. description
    Ultra-deep sequencing will be performed on cfDNA to assess the feasibility of detecting mutations of NRAS from peripheral blood samples.
    id
    OG001
    title
    Detection of NRAS Mutations Using cfDNA
  3. description
    Ultra-deep sequencing will be performed on cfDNA to assess the feasibility of detecting mutations of BRAF from peripheral blood samples.
    id
    OG002
    title
    Detection of BRAF Mutations Using cfDNA
param Type
NUMBER
population Description
64 cfDNA specimens from 53 Myeloma patients including 13 patients from this trial that were included in this analysis
reporting Status
POSTED
time Frame
Baseline and every even cycle and at progression, an average of 9 cycles (9 months)
title
Detection of RAS and RAF Mutations Using cfDNA
type
OTHER_PRE_SPECIFIED
unit Of Measure
MUTATIONS

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice